Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders

Mycoses

Volumn 50, Issue SUPPL. 1, 2007, Pages 2-17

  Maertens, Johan ^a   Theunissen, Koen ^a   Lodewyck, Tom ^a   Lagrou, Katrien ^a   Van Eldere, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

D glucan; Aspergillosis; Diagnosis; Galactomannan; Neutropenia; Pre emptive

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIGEN; BETA GLUCAN; BETA LACTAM; CEFEPIME; ECHINOCANDIN; GALACTOMANNAN; GENOMIC DNA; ITRACONAZOLE; MEROPENEM; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY EB A2; POSACONAZOLE; STEROID; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIGEN DETECTION; ASPERGILLOSIS; CLINICAL FEATURE; COST; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DNA SEQUENCE; FEBRILE NEUTROPENIA; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RADIODIAGNOSIS; REVIEW; SERODIAGNOSIS; SPECIES INVASION; STEROID THERAPY; TOXICITY; TREATMENT RESPONSE;

ANTIGENS, FUNGAL; ASPERGILLOSIS; ASPERGILLUS; BETA-GLUCANS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOASSAY; MANNANS; SEROLOGIC TESTS;

ASPERGILLUS;

EID: 33947710090     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2007.01375.x     Document Type: Review

References (119)

1. Perea S, Patterson TF. Invasive Aspergillus infections in hematologic malignancy patients. Semin Respir Infect 2002; 17: 99-105.
2. Cordonnier C, Ribaud P, Herbrecht R et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42: 955-63.
3. Blijlevens NM, Donnelly JP, de Pauw BE. Microbiologic consequences of new approaches to managing hematologic malignancies. Rev Clin Exp Hematol 2005; 9: E2.
4. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
5. Marr KA, Carter Ra, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
6. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005; 43 (Suppl. 1): S207-38.
7. Stevens DA. Diagnosis of fungal infections: current status. J Antimicrob Chemother 2002; 49 (Suppl. 1): S11-9.
8. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
9. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002; 21: 161-72.
10. Yeo SF, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev 2002; 15: 465-84.
11. Young R, Bennett JE. Invasive aspergillosis: absence of detectable antibody response. Am Rev Respir Dis 1971; 104: 710-6.
12. Bardana EJ, Gerber JD, Craig S, Cianciulli FD. The general and specific humoral immune response to pulmonary aspergillosis. Am Rev Respir Dis 1975; 112: 799-805.
13. Tomee JFC, Mannes GPM, van der Bij W et al. Serodiagnosis and monitoring of Aspergillus infections after lung transplantation. Ann Intern Med 1996; 125: 197-201.
14. Lehmann PF, Reiss E. Invasive aspergillosis: antiserum for circulating antigen produced after immunization with serum from infected rabbits. Infect Immun 1978; 20: 570-2.
15. Reiss E, Lehmann PF. Galactomannan antigenemia in invasive aspergillosis. Infect Immun 1979; 25: 357-65.
16. Bennett JE, Bhattacharjee AK, Glaudemans CPJ. Galactofuranosyl groups are immunodominant in Aspergillus fumigatus galactomannan. Mol Immun 1985; 22: 251-4.
17. Latge JP, Kobayashi H, Debeaupuis JP et al. Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus. Infect Immun 1994; 62: 5424-33.
18. Morelle W, Bernard M, Debeaupuis JP, Buitrago M, Tabouret M, Latgé JP. Galactomannoproteins of Aspergillus fumigatus. Eukaryot Cell 2005; 4: 1308-16.
19. Mennink-Kersten MASH, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349-57.
20. Weiner MH. Antigenemia detected by radioimmunoassay in systemic aspergillosis. Ann Intern Med 1980; 92: 793-6.
21. Andrew CP, Weiner MH. Immunodiagnosis of invasive pulmonary aspergillosis in rabbits. Fungal antigen detected by radioimmunoassay in bronchoalveolar lavage fluid. Am Rev Respir Dis 1981; 124: 60-4.
22. Andrew CP, Weiner MH. Aspergillus antigen detection in bronchoalveolar lavage fluid from patients with invasive aspergillosis and aspergilloma. Am J Med 1982; 73: 372-80.
23. Weiner MH, Talbot GH, Gerson SL, Filice G, Cassileth PA. Antigen detection in the diagnosis of invasive aspergillosis. Utility in controlled, blinded trials. Ann Intern Med 1983; 99: 777-82.
24. Talbot GH, Weiner MH, Gerson SL, Provencher M, Hurwitz S. Serodiagnosis of invasive aspergillosis in patients with hematologic malignancy: validation of the Aspergillus fumigatus antigen radioimmunoassay. J Infect Dis 1987; 155: 12-27.
25. Dupont B, Huber M, Kim SJ, Bennett JE. Galactomannan antigenemia and antigenuria in aspergillosis: studies in patients and experimentally infected rabbits. J Infect Dis 1987; 155: 1-11.
26. Sabetta JR, Miniter P, Andriole VT. The diagnosis of invasive aspergillosis by an enzyme-linked immunosorbent assay for circulating antigen. J Infect Dis 1985; 152: 946-53.
27. De Repentigny L, Boushira M, Ste-Marie L, Bosisio G. Detection of galactomannan antigenemia by enzyme immunoassay in experimental invasive aspergillosis. J Clin Microbiol 1987; 25: 863-7.
28. Wilson EV, Hearn VM, Mackenzie DWR. Evaluation of a test to detect circulating Aspergillus fumigatus antigen in a survey of immunocompromised patients with proven or suspected invasive disease. J Med Vet Mycol 1987; 25: 365-74.
29. Bennett JE, Friedman MM, Dupont B. Receptor-mediated clearance of Aspergillus galactomannan. J Infect Dis 1987; 155: 1005-10.
30. Stynen D, Safarti J, Goris A et al. Rat monoclonal antibodies against Aspergillus galactomannan. Infect Immun 1992; 60: 2237-45.
31. Swanink CMA, Meis JFGM, Rijs AJMM, Donnelly JP, Verweij PE. Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol 1997; 35: 257-60.
32. Van Cutsem J, Meulemans L, Van Gerven F, Stynen D. Detection of circulating galactomannan by Pastorex Aspergillus in experimental invasive aspergillosis. Mycoses 1990; 33: 61-9.
33. Dupont B, Improvisi L, Provost F. galactomannane dans les aspergilloses invasives humaines et animales avec un test au latex. Bull Soc Fr Mycol Med 1990; 19: 35-41.
34. Rogers T, Haynes K, Barnes R. Value of antigen detection in predicting invasive pulmonary aspergillosis. Lancet 1990; 336: 1210-3.
35. Haynes K, Rogers T. Retrospective evaluation of a latex agglutination test for diagnosis of invasive aspergillosis in immunocompromised patients. Eur J Clin Microbiol Infect Dis 1994; 13: 670-4.
36. Verweij PE, Stynen D, Rijs AJMM, De Pauw BE, Hoogkamp-Korstanje JAA, Meis JFGM. Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol 1995; 33: 1912-4.
37. Sulahian A, Tabouret M, Ribaud P et al. Comparison of enzyme immunoassay and latex agglutination test detection of galactomannan in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis 1996; 15: 139-45.
38. Kappe R, Schulze-Berge A, Sonntag HG. Evaluation of eight antibody tests and one antigen test for the diagnosis of invasive aspergillosis. Mycoses 1996; 39: 13-23.
39. Machetti M, Feasi M, Mordini N et al. Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Bone Marrow Transplant 1998; 21: 917-21.
40. Herrmann J, Gugel A, Freidank H, Bertz H, Finke J. Aspergillus antigen detection: comparison of a new sandwich ELISA and the latex agglutination test in patients with histologically proven invasive aspergillosis. Mycoses 1998; 41 (Suppl. 1): S83-5.
41. Kappe R, Schulze-Berge A. New cause for false-positive results with the Pastorex Aspergillus antigen latex agglutination test. J Clin Microbiol 1993; 31: 2489-90.
42. De Repentigny L. Serodiagnosis of candidiasis, aspergillosis, and cryptococcosis. Clin Infect Dis 1992; 14 (Suppl. 1): S11-22.
43. Lijmer J, Mol BW, Heisterkamp S et al. Empirical evidence of design-related bias in studies of diagnostic test. JAMA 1999; 282: 1061-6.
44. Whiting P, Rutjes AWS, Reitsma JB et al. Sources of variation and bias in studies of diagnostic accuracy. A systematic review. Ann Intern Med 2004; 140: 189-202.
45. Fischer JE, Bachmann LM, Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 2003; 29: 1043-51.
46. Cimolai N. Serodiagnosis for bacterial infections. In: Cimolai N (ed.), Laboratory Diagnosis of Bacterial Infections. New York, Basel: Marcel Dekker, Inc., 2001: 55-82.
47. Stynen D, Goris A, Sarfati J, Latgé JP. A new sensitive sandwich ELISA to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995; 33: 497-500.
48. Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. Transplant Infect Dis 2003; 5: 158-66.
49. Rohrlich P, Sarfati J, Mariani P et al. Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. Pediatr Infect Dis 1996; 15: 232-7.
50. Bretagne S, Marmorat-Khuong A, Kuentz M, Latgé JP, Bart-Delabesse E, Cordonnier C. Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients. J Infect 1997; 35: 7-15.
51. Bretagne S, Costa JM, Bart-Delabesse E, Dhedin N, Rieux C, Cordonnier C. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis 1998; 26: 1407-12.
52. Maertens J, Verhaegen J, Demuynck H et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37: 3223-8.
53. Maesaki S, Kawamura S, Hashiguchi K et al. Evaluation of sandwich ELISA galactomannan test in samples of positive LA test and positive Aspergillus antibody. Intern Med 1999; 38: 948-50.
54. Williamson ECM, Oliver DA, Johnson EM, Foot ABM, Marks DI, Warnock DW. Aspergillus antigen testing in bone marrow transplant recipients. J Clin Pathol 2000; 53: 362-6.
55. Ulusakarya A, Chachaty E, Vantelon JM et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J 2000; 1: 111-6.
56. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-10.
57. Sulahian A, Boutboul F, Ribaud P, Leblanc T, Lacroix C, Derouin F. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric haematology units during a 4-year prospective study. Cancer 2001; 91: 311-8.
58. Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002; 186: 1297-306.
59. Herbrecht R, Letscher-Bru V, Oprea C et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20: 1898-906.
60. Rovira M, Jimenez M, De la Bellacasa JP et al. Detection of Aspergillus galactomannan by enzyme immunosorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study. Transplantation 2004; 77: 1260-4.
61. Maertens J, Theunissen K, Verbeken E et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic patients and haematological stem cell transplant recipients. Br J Haematol 2004; 126: 852-60.
62. Pereira CN, Del Nero G, Lacaz CS, Machado CM. The contribution of galactomannan detection in the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Mycopathologica 2005; 159: 487-93.
63. Fortun J, Martin-Davila P, Alvarez M et al. for the Ramon y Cajal Hospital's Liver Transplant Group. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation 2001; 71: 145-9.
64. Husain S, Kwak EJ, Obman A et al. Prospective assessment of Platelia™ Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4: 796-802.
65. xzKwak EJ, Husain S, Obman A et al. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004; 42: 435-8.
66. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641-9.
67. Becker MJ, Lugtenburg EJ, Cornelissen JJ, van der Schee C, Hoogsteden HC, de Marie S. Galactomannan detection in CT-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121: 448-57.
68. Jarque I, Andreu R, Salavert M et al. Value of Aspergillus galactomannan antigen detection in the diagnosis and follow-up of invasive aspergillosis in hematological patients (Spanish). Rev Iberoam Micol 2003; 20: 116-8.
69. Moragues MD, Amutio E, Garcia-Ruiz JC, Ponton J. Usefulness of galactomannan detection in the diagnosis and follow-up of hematological patients with invasive aspergillosis (Spanish). Rev Iberoam Micol 2003; 20: 103-10.
70. Pazos C, del Palacio A. Early diagnosis of invasive aspergillosis in neutropenic patients with bi-weekly serial screening of circulating galactomannan by Platelia Aspergillus (Spanish). Rev Iberoam Micol 2003; 20: 99-102.
71. Pinel C, Fricker-Hidalgo H, Lebeau B et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 2003; 41: 2184-6.
72. Buchheidt D, Hummel M, Schleiermacher D et al. Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 125: 196-202.
73. Yoo JH, Choi JH, Choi SM et al. Application of nucleic acid sequence-based amplification for diagnosis of and monitoring the clinical course of invasive aspergillosis in patients with hematologic diseases. Clin Infect Dis 2005; 40: 392-8.
74. Platelia [package insert]. Bio-Rad, Marnes-La-Coquette.
75. Berenguer J, Allende MC, Lee JW et al. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporin and methyl-prednisolone- induced immunosuppression. Am J Respir Crit Care Med 1995; 152: 1079-86.
76. Stephens-Romero SD, Mednick AJ, Feldmesser M. The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy. Infect Immun 2005; 73: 114-25.
77. Balloy V, Huerre M, Latgé JP, Chignard M. Differences in patters of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005; 73: 494-503.
78. Verweij PE, Weemaes CM, Curfs JHAJ, Bretagne S, Meis JFGM. Failure to detect circulating Aspergillus markers in a patients with chronic granulomatous disease and invasive aspergillosis. J Clin Microbiol 2000; 38: 3900-1.
79. Ascioglu S, Rex JH, De Pauw B et al. on behalf of the Invasive Fungal infections Cooperative Group of the European Organization for Research and Treatment of Cancer and Mycoses Study group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
80. Verweij PE, Erjavec Z, Sluiters W et al. Detection of antigen in sera of patients with invasive aspergillosis: intra-and interlaboratory reproducibility. The Dutch Interuniversity Working Party for Invasive Mycoses. J Clin Microbiol 1998; 36: 1612-6.
81. Verweij P, Masson C, Klont R, Heinen C, Crepin B, Maertens J. Optimisation of the Cut-off Value of the Platelia™ Aspergillus ELISA. 16th European Congress of Clinical Microbiology and Infectious Diseases, Nic, 2006.
82. Siemann M, Koch-Dorfler M, Gaude M. False-positive results in premature infants with the Platelia Aspergillus sandwich enzyme-linked immunosorbent assay. Mycoses 1998; 41: 373-7.
83. Mennink-Kersten MASH, Klont RR, Warris A, Op den Camp HJM, Verweij PE. Bifidobacterium lipoteichoic acid and false reactivity in Aspergillus antigen detection. Lancet 2004; 363: 325-7.
84. Mennink-Kersten MASH, Ruegebrink D, Klont RR et al. Bifidobacterial lipoglycan as a new cause for false-positive Platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J Clin Microbiol 2005; 43: 3925-31.
85. Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349: 2366-7.
86. Viscoli C, Machetti M, Cappellano P et al. False-positive galactomannan Platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913-6.
87. Adam O, Aupérin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004; 38: 917-20.
88. Singh N, Obman A, Husain S, Aspinall S, Mietzner S, Stout JE. Reactivity of Platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum. Antimicrob Agents Chemother 2004; 48: 1989-92.
89. Walsh TJ, Shoham S, Petraitiene R et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 2004; 42: 4744-8.
90. Penack O, Schwartz S, Thiel E, Blau IW. Lack of evidence that false-positive Aspergillus galactomannan antigen test results are due to treatment with piperacillin-tazobactam. Clin Infect Dis 2004; 39: 1401-2.
91. Wu DH. Platelia Aspergillus assay and potential cross-reaction. Clin Infect Dis 2004; 39: 1402.
92. Adam O, Aupérin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E. Reply to Penack et al. and Wu. Clin Infect Dis 2004; 39: 1402.
93. Mattei D, Rapezzi D, Mordini N et al. False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol 2004; 42: 5362-3.
94. Maertens J, Theunissen K, Verhoef G, Van Eldere J. False-positive Aspergillus galactomannan antigen test results. Clin Infect Dis 2004; 39: 289-90.
95. Hamaki T, Kami M, Kanda Y et al. False-positive results of Aspergillus enzyme-linked immunosorbent assay in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 633-4.
96. Petraitiene R, Petraitis V, Groll AH et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45: 857-69.
97. Francis P, Lee JW, Hoffman A et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis 1994; 169: 356-68.
98. Martino R, Viscoli C. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 2005; 132: 138-54.
99. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-9.
100. Hope WW, Denning DW. Invasive aspergillosis: current and future challenges in diagnosis and therapy. Clin Microbiol Infect 2004; 10: 2-4.
101. Hope WW, Walsh T, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005; 5: 609-22.
102. Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography-based pre-emptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-50.
103. Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253-9.
104. Boutboul F, Albert C, Leblanc T et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34: 939-43.
105. Scotter JM, Chambers ST. Comparison of galactomannan detection, PCR-enzyme-linked immunosorbent assay, and real-time PCR for diagnosis of invasive aspergillosis in a neutropenic rat model and effect of caspofungin acetate. Clin Diagn Lab Immunol 2005; 12: 1322-7.
106. Klont R, Ruegebrink D, Mennink-Kersten M et al. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis 2006; 43: e23-5.
107. Maertens J, Glasmacher A, Selleslag D et al. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis 2005; 41: e9-e14.
108. Miyazaki T, Kohno S, Mitsutake K et al. Plasma (1->3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol 1995; 33: 3115-8.
109. Obayashi T, Yoshida M, Mori T et al. Plasma (1->3)-beta-D- glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345: 17-20.
110. Kami M, Tanaka Y, Kanda Y et al. Computed tomographic scan of the chest, latex agglutination test and plasma (1AE3)-beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Haematologica 2000; 85: 745-52.
111. Odabasi Z, Mattiuzzi G, Estey E et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff, development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
112. Ostrosky-Zeichner L, Alexander B, Kett D et al. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-9.
113. Upton A, Leisenring W, Marr K. (1->3) beta-D-Glucan assay in the diagnosis of invasive fungal infections. Clin Infect Dis 2006; 42: 1054-6.
114. Mennink-Kersten M, Warris A, Verweij P. 1,3-beta-D-Glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006; 354: 2834-5.
115. Pickering J, Sant H, Bowles C et al. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43: 5957-62.
116. Klont RR, Mennink-Kersten MASH, Verweij PE. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 2004; 39: 1467-74.
117. Kawazu M, Kanda Y, Nannya Y et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1,3)-β-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42: 2733-41.
118. Chamilos G, Luna M, Lewis RE et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-9.
119. Pazos C, Ponton J, del Palacio A. Contribution of (1 → 3)-β-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43: 299-305.